瘤细胞可以通过对干扰素受体表达的免疫编辑来逃避干扰素-β的抗增殖压力
Felix Hiebinger1,2, Aiste Kudulyte1,3, Huanting Chi4,5
1Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", Division Virus-Associated Carcinogenesis (F170), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cancer cell international
|December 9, 2023
概括
瘤细胞可以对I型干扰素 (IFN) 的增长抑制作用产生抵抗,干扰素是免疫反应的关键部分. 这种与减少IFNAR2受体表达相关的耐药性可能会推动癌症的演变和影响治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- I型干扰素 (IFN) 对先天免疫和抗瘤反应至关重要,影响细胞增殖.
- 慢性炎症相关的癌症可能面临不断的IFN暴露的选择性压力,推动瘤的演变.
- 抗IFN的癌症亚克隆可以出现,有助于瘤免疫编辑和潜在的更具攻击性的疾病.
研究的目的:
- 研究癌细胞中IFN不敏感性的发展和分子机制.
- 探索IFN暴露在塑造瘤进化和耐药性的作用.
- 为了确定潜在的生物标志物来分层患者的IFN为基础的疗法.
主要方法:
- 细胞在体外暴露于干扰素β (IFN-β) 六周以诱导耐药性.
- 评估IFN治疗细胞的抗增殖作用和表型稳定性.
- 在10个肝癌细胞系中对IFN-β增长抑制的细胞敏感性的分析.
- 与IFN敏感性相关的IFNAR2受体表达的量化.
主要成果:
- 六周的IFN-β暴露在体外诱导了对其抗增殖作用的稳定耐药性.
- 在肝癌细胞系中观察到IFN-β敏感性的显著变化,非分化的细胞系是最不敏感的.
- 在长期的IFN选择细胞和非分化瘤细胞系中,一致发现IFNAR2表达的减少.
- 在瘤进化过程中,IFNAR2似乎是IFN耐药性发展的关键标.
结论:
- IFN耐药性是一种稳定的表型,可以通过长时间的IFN暴露而发展,或是某些癌症类型的固有特征.
- 减少IFNAR2表达是癌症中IFN不敏感的可能机制.
- 了解IFN耐药机制对于开发有效的个性化癌症疗法和生物标志物至关重要.
更多相关视频
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K


